Mr. Yan has over 20 years of experience specializing in cell signal transduction and cancer biology. He has expertise in high throughput screening against validated enzyme targets including protein kinases. Prior to co-founding SignalChem Pharmaceuticals Inc. in 2004, Mr. Yan held senior research positions at Kinetek Pharmaceuticals Inc. and QLT Inc., where he was playing leading roles in novel drug target validation and pipeline development of kinase inhibitors. With his leadership, Jun has built SignalChem Pharmaceuticals Inc into a very profitable business with higher than 20% annual increase in revenue which has been a leading supplier of cell signaling bioreagents for drug discovery and biomedical research. In 2010, Mr. Yan co-founded MetaSignal Therapeutics Inc., a company focusing on developing and commercializing anti-cancer drugs targeting CAIX, a well-known cancer related enzyme. Mr. Yan brings to SLC expertise in kinase biology and has been the driving force of the SLC’s kinase-focused drug discovery platform.

Dr. Zaihui Zhang is a co-founder of Signalchem Lifesciences Corporation. He has over 25 years of experience in the development of novel targeted therapies. He has successfully led a wide range of therapeutic programs across different disease areas and has experience working with different classes of biological targets including protein kinases, metallo-enzymes, sodium channels, and transporters. Dr. Zhang has led several therapeutic programs that have been successfully acquired by or partnered with top tier multinational pharmaceutical companies and biotech companies during his tenures at Xenon Pharmaceuticals Inc. and Kinetek Pharmaceuticals Inc.. He has played pivotal roles in advancing four small molecules from the discovery stage to the clinical stage. He is a co-author of more than 30 scientific publications and is an inventor/co-inventor of more than 80 patents and patent applications. He brings to SLC expertise in all stages of drug discovery including hit-to-lead, lead optimization, preclinical development, project management and leadership, and intellectual property. Dr. Zhang received his Ph.D. in chemistry from the University of British Columbia.

Mr. Quan has senior management experience in private and publicly traded companies for over 25 years. He has served as Senior Financial officer in many biotechnology companies and government funded institutes including Kinetek Pharmaceuticals Inc., Genome BC, Aquinox, Welichem Biotech and SignalChem. Harvey brings to SLC expertise in financial operations management for drug development and biotechnology companies.

Mr. Chen has more than 25 years of experience in finance management, mergers & acquisitions, financing and business development in a cross-culture environment. He is currently the managing director of DoubleOcean Financial Group, a financial advisory firm that facilitates the cross-border investments between North America and China. Mr. Chen has extensive experiences with public companies listed on TSX and Hong Kong Stock Exchange in the capacity of director of board and/or CFO, including pharmaceutical companies such as Wex Pharmaceuticals and Polo Biology Group, as well as mining companies such as Spur Ventures and Commander Resources and financial services company G-Resources Group Ltd. (HKSE: 1051). He also served as VP Finance of a mining company with investments of $700 million in Yukon between 2012 and 2014. Prior to moving to Canada, Mr. Chen worked in various management positions for eight years at Honeywell International and United Technologies in the United States, two Fortune 500 companies. Mr. Chen received his Bachelor's degree in International Finance from Peking University, China and his Master's in Business Administration from the University of Arizona, USA. He is a Certified Public Accountant in the United States.

Dan has more than 25 years’ experience in drug development, business planning, funding, partnerships, and licensing. First as an executive with Daiichi Sankyo, later with Novo Nordisk, Dan was the founder and CEO of ChemoMab, a startup raising capital successfully and later with a successful exit. Dan was an Assistant Professor of Immunology at UCLA, completed his residency and fellowship at Yale University school of medicine. Dan received his medical degree in Israel.

Dr. Fabbro started his career as Group Leader in the Molecular Tumor Biology Unit of the University of Basel (1979-1991) working mainly on the mechanisms of activation of PKC as well as on prognostic markers for breast cancer. In 1991, he joined the Pharmaceuticals Research of Ciba-Geigy Basel, first as a Group Leader in the department of Oncology, which then led to the successful discovery of Midostaurin (PKC412) and Glivec (STI571). In 1994, as Indication Area Head Oncology, he directed research on inhibitors of various kinases, SH2, p53/hdm2, and antisense projects in collaboration with ISIS Pharmaceuticals. Following the merger of Ciba-Geigy with Sandoz to form Novartis in 1996, he actively contributed as member of the integration team Oncology to forge the Novartis and later the NIBR Onocology Research (as it is today), where he was responsible for the preclinical world-wide drug discovery efforts focusing on ATP-dependent enzymes (protein kinases and ATPases), as well as MT stabilizing agents like EPO906 (Patupilone, Phase III) and from 2004 to 2005 he served as Head of Signaling Pathways in the Oncology Research of NIBR. In 2006, Dr Fabbro, implement the kinase platform at NIBR, where he served as head of the Kinase Biology Unit of the EPK until 2012. During his pharmaceutical drug discovery career he has contributed amongst significantly to the discovery and development of various protein kinase inhibitors for the treatment of cancer, including various preclinical and clinical candidates, including the PI3K inhibitors (BEZ235, BKM120 and BYL719 in Phase I-III clinical trials) PTK787 (Vatalinib, Phase-III clinical trial), PKC412 (Midostaurin, Phase III clinical trial), and was involved in the the launch of compounds like RAD001 (Everolimus), STI571 (Imatinib, Glivec) and AMN107 (Nilotinib, Tasigna). In 2013, D. Fabbro joined PIQUR Therapeutics AG, Basel, as Chief Scientific Officer.

Dr. Gordon B. Mills earned his M.D. and his Ph.D. in biochemistry and completed his training in Obstetrics and Gynecology at the University of Alberta. Dr. Mills is currently chair of the Department of Systems Biology, Co-Director of the Kleberg Center for Molecular Markers and holds the Olga Keith Wiess Distinguished University Chair for Cancer Research at the MD Anderson Cancer Center. Dr. Mills’ research interests include using genomics and molecular markers to track the initiation, progression and management of cancer, lysolipid growth factors in cancer and endocytic recycling, bioenergetics and autophagy. Dr. Mills has more than 500 publications in high impact journals including Nature, Cell, Oncogene, Nature Genetics, Nature Medicine, Nature Cell Biology, Nature Cancer Reviews, Cancer Research, Proceedings of the National Academy of Sciences and Clinical Cancer Research. As a testament to the quality of his research, Dr. Mills’ work in ovarian cancer, breast cancer and tumor immunology has been continuously funded by major peer-reviewed grants for over 25 years. Dr. Mills is also the holder of more than 20 patents related to novel technologies and molecular markers. He was a co-founder of an early diagnostics company. Dr. Mills currently sits on the scientific advisory boards of multiple companies and venture capital groups. Based on his expertise in technology development, he was the founding chair of the MD Anderson Cancer Center Technology Review Committee.

Dr. Karen Gelmon is Co-Chair of the Breast Site Committee for the NCIC Clinical Trials Group and a member of the NCI Breast Steering Committee and of the BIG (Breast International Group) Advisory Group. She sits on the NCIC-CTG IND executive and is a past chair of this committee. Dr. Gelmon is a clinical leader of Advanced Therapeutics department at the BC Cancer Agency. She sits on the international advisory board of The Lancet, The Lancet Oncology, The Oncologist and Clinical Breast Cancer. Dr. Gelmon is a reviewer for journals and grant review panels and recently has become a member of the scientific advisory council for the Susan Komen Foundation. She has been track chair for breast cancer at ASCO and currently sits on the education committee. Dr. Gelmon is an active teacher interested in education of health care professionals and the public and has published extensively. She has been a member of the board of the BC Cancer Foundation, on the medical advisory board of the BC/Yukon Chapter of the Canadian Breast Cancer Foundation. She also sits on the board of Rethink Breast Cancer. Dr. Gelmon was the recipient of a YWCA Woman of Distinction award in 2003.

Dr. Lang has more than 30 years of experience in medicinal chemistry of which he has spent 20 years in the field of Oncology and Immunology. Dr. Lang has contributed to three multi-billion Novartis drugs on the market (Femara®, Reyataz® and Tasigna®), and five promising drug candidates in clinical trials. Until October 2012, he was Head of Medicinal Chemistry for Oncology research programs at Novartis Pharma AG.

Dr. Dedhar is a world expert in cancer biology and cell adhesion mechanisms and signal transduction with expertise in in vivo models of invasion and metastasis. With more than 30 years of experience in cancer research, Dr Dedhar has authored more than 170 publications in the cancer field and holds a number of patents. His projects have received significant funding from CIHR, CBRCA, and CCSRI. Dr Dedhar is the discoverer of Integrin Linked Kinase (ILK), a major target for cancer, cardiovascular disease and inflammation. He is also the discoverer of the enzyme target, CAIX, used in SLC’s hypoxia anticancer drug development program. He currently holds the position of Distinguished Scientist – Genetics Unit, Integrative Oncology at the BC Cancer Research Centre.

Dr. Supuran is a world renowned medicinal chemist and has 22 years of research experience with projects financed by the EU and many private drug companies. He is a world expert on the chemistry of the hypoxia CAIX anticancer drug program inhibitors and activators. Dr. Supuran is co-author on more than 670 scientific publications and patents. He currently holds the position of Professor, Faculty of Pharmacy, Department of Chemistry, University of Florence.